152 related articles for article (PubMed ID: 21421652)
1. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension.
Zhenfeng Zheng ; Huilan Shi ; Junya Jia ; Dong Li ; Shan Lin
J Renin Angiotensin Aldosterone Syst; 2011 Sep; 12(3):365-74. PubMed ID: 21421652
[TBL] [Abstract][Full Text] [Related]
2. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
[TBL] [Abstract][Full Text] [Related]
3. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
[TBL] [Abstract][Full Text] [Related]
4. A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension.
Zhao D; Liu H; Dong P
Clin Exp Hypertens; 2019; 41(1):75-79. PubMed ID: 29589977
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group.
Gradman AH; Lewin A; Bowling BT; Tonkon M; Deedwania PC; Kezer AE; Hardison JD; Cushing DJ; Michelson EL
Heart Dis; 1999; 1(2):52-7. PubMed ID: 11720604
[TBL] [Abstract][Full Text] [Related]
6. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension.
Meredith PA; Murray LS; McInnes GT
J Hum Hypertens; 2010 Aug; 24(8):525-31. PubMed ID: 20016523
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension.
Zhenfeng Zheng ; Huilan Shi ; Junya Jia ; Dong Li ; Shan Lin
J Renin Angiotensin Aldosterone Syst; 2011 Jun; 12(2):102-12. PubMed ID: 21059822
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan.
Russell D; Stålhammar J; Bodegard J; Hasvold P; Thuresson M; Kjeldsen SE
J Clin Hypertens (Greenwich); 2011 Mar; 13(3):189-97. PubMed ID: 21366850
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY
Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046
[TBL] [Abstract][Full Text] [Related]
11. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
Palma-Gamiz JL; Pêgo M; Marquez E; Pujol M; Olivan J; Alegría E; Sagastagoitia-Gorostiza JD; Gonzalez-Juanatey JR
Clin Drug Investig; 2007; 27(6):407-17. PubMed ID: 17506591
[TBL] [Abstract][Full Text] [Related]
12. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
Grosso AM; Bodalia PN; Macallister RJ; Hingorani AD; Moon JC; Scott MA
Int J Clin Pract; 2011 Mar; 65(3):253-63. PubMed ID: 21284790
[TBL] [Abstract][Full Text] [Related]
13. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics.
Rayner BL; Trinder YA; Baines D; Isaacs S; Opie LH
Am J Hypertens; 2006 Feb; 19(2):208-13. PubMed ID: 16448895
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension.
Xi GL; Cheng JW; Lu GC
Am J Hypertens; 2008 May; 21(5):546-52. PubMed ID: 18437146
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
Lacourcière Y; Neutel JM; Schumacher H
Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
[TBL] [Abstract][Full Text] [Related]
16. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A;
J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316
[TBL] [Abstract][Full Text] [Related]
17. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
19. Candesartan cilexetil: an angiotensin II receptor blocker.
Stoukides CA; McVoy HJ; Kaul AF
Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Usher-Smith J; Ramsbottom T; Pearmain H; Kirby M
Int J Clin Pract; 2008 Mar; 62(3):480-4. PubMed ID: 18201178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
